Heat-resistant fatty acid photo-decarboxylase mutant based on continuous site combination mutation and application of heat-resistant fatty acid photo-decarboxylase mutant

By performing continuous site combination mutations on fatty acid photodecarboxylase, the heat-resistant mutant M8 is formed, which solves the problem of the reduction of natural enzyme activity at high temperature, and achieves efficient catalysis above 50°C without the need for organic solvents. Improves the potential of biofuel production.

CN119040308AActive Publication Date: 2024-11-29DALIAN UNIV OF TECH

Patent Information

Application Number
CN202411439579.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-15
Publication Date
2024-11-29
Estimated Expiration
2044-10-15

AI Technical Summary

Technical Problem

Natural fatty acid photodecarboxylase has almost no catalytic activity at above 50°C, and the substrate is difficult to dissolve in water, limiting its industrial-scale application.

Method used

Through continuous site combination mutation technology, fatty acid photodecarboxylase is subjected to 8-site combination mutations of Q410N, K413T, G422F, G423R, R424S, G426P, T428A, and S429T to improve the heat resistance and stability of the enzyme and form heat-resistant fatty acids. The photodecarboxylase mutant M8 can maintain activity above 50°C and catalyze the decarboxylation reaction of fatty acids without the need for organic solvents to be aided.

Benefits of technology

The relative activity of mutant M8 at 50°C was increased by 3 times, and it can efficiently catalyze the conversion of myristic acid into tridecane, significantly improving the catalytic efficiency in the presence of helpless solvents, prolonging the half-life of the enzyme, and improving the high temperature. Application potential under conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040308A_ABST
    Figure CN119040308A_ABST
Patent Text Reader

Abstract

The invention discloses a heat-resistant fatty acid light decarboxylase mutant based on continuous site combination mutation and application thereof, and belongs to the technical field of enzyme engineering. A continuous site combination mutant library is constructed aiming at the chlorella-derived fatty acid light decarboxylase CvFAP, an 8-site combination mutant M8 is screened, the optimal reaction temperature of the combination mutant M8 is 45 DEG C and is increased by 15 DEG C compared with that of the CvFAP, 50% of activity of the combination mutant M8 is reserved under the condition of 55 DEG C, and the CvFAP almost has no activity at the temperature. The method breaks through the limitation that the optimum catalytic temperature of the conventional CvFAP is 30 DEG C and the substrate fatty acid depends on the hydrotropy of organic solvents such as dimethyl sulfoxide and the like. Under the conditions that the temperature is 55 DEG C higher than the melting point of myristic acid and no organic solvent is used for assisting dissolving, the myristic acid is efficiently catalyzed by whole cells containing the mutant M8 to generate tridecane. The invention provides a prospect for the application of the fatty acid photo-decarboxylase under the conditions of high temperature and no need of an organic cosolvent.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of enzyme engineering, and in particular relates to a heat-resistant fatty acid photodecarboxylase mutant based on continuous site combination mutation and application thereof. Background Art

[0002] Fatty Acid Photodecarboxylase (FAP) is found in microalgae and can catalyze the conversion of fatty acids into biofuels such as alkanes or alkenes, thereby reducing dependence on non-renewable resources such as petroleum. Therefore, it has a broad application background. However, there are many problems with the application of fatty acid photodecarboxylase, such as low thermal stability, a half-life of less than 60 minutes, and a significant decrease in activity above 50°C. It has also been reported that its photostability is sensitive, and the tertiary structure of FAP protein is destroyed under long-term blue light irradiation, resulting in a decrease in enzyme activity.

[0003] The most typical fatty acid photodecarboxylase comes from Chlorella variabilis NC64A. The optimum temperature of the enzyme is 30°C, and the activity at 50°C is about 35% of the optimum temperature. Above 55°C, the enzyme has almost no activity. However, the substrate fatty acid is usually insoluble in water. At present, in the process of FAP-catalyzed fatty acid decarboxylation, fatty acids are usually dissolved in organic cosolvents such as dimethyl sulfoxide. Due to the influence of organic cosolvents on enzyme activity, the concentration of fatty acid substrates cannot be increased to a higher concentration, which is commonly reported to be 10-65mM, limiting its industrial-scale application.

[0004] Among the common fatty acid substrates of fatty acid photodecarboxylase, the melting point of lauric acid is 44.2°C, the melting point of myristic acid is 54.4°C, and the melting point of palmitic acid is 62.9°C. If a fatty acid decarboxylase mutant with heat resistance and high stability can be developed, especially one that retains activity above 55-60°C, it will effectively solve the problems of low thermal stability and difficult substrate solubility, and will have great prospects in industrial applications.

[0005] Common thermal stability improvement technologies include amino acid mutations in the distal loop region, introduction of hydrogen bonds and other interactions, etc., mainly including site-directed mutagenesis and iterative combination mutagenesis. The advantage of site-directed mutagenesis is that the stability of the enzyme can be improved by precisely modifying specific amino acid residues, while iterative combination mutagenesis allows the introduction of multiple mutations at the same time to enhance the overall thermal stability of the enzyme. However, in the process of FAP modification, due to the synergistic effects between adjacent amino acids, they affect each other, making it difficult for the effects of beneficial mutations to accumulate. However, so far, there has been no report on the related research on directly optimizing and strengthening the interactions between adjacent amino acids through continuous mutations, reducing the non-additive effects in the subsequent combination of mutation sites, and obtaining heat-resistant fatty acid photodecarboxylase mutants. Summary of the invention

[0006] To solve the above problems, the purpose of the present invention is to provide a heat-resistant fatty acid photodecarboxylase mutant based on continuous site combination mutation and its application, which solves the technical problem that the natural fatty acid photodecarboxylase CvFAP has almost no catalytic activity above 50°C, and can be used to catalyze the decarboxylation of fatty acids and the synthesis of alkanes under high temperature conditions exceeding the melting point of fatty acids and without organic solvent solubilization conditions.

[0007] In order to achieve the above object, the present invention provides the following technical solutions:

[0008] In a first aspect, the present invention provides a thermostable fatty acid photodecarboxylase mutant, the amino acid sequence of the thermostable fatty acid photodecarboxylase mutant is shown in SEQ ID NO.3.

[0009] Based on the above technical scheme, further, the heat-resistant fatty acid photodecarboxylase mutant increases protein stability by reducing the free energy of the overall protein structure through molecular dynamics stability calculation and site-directed mutagenesis. The mutant is obtained by performing continuous site combination mutations on the fatty acid photodecarboxylase of the amino acid sequence such as amino acid residues 77-645 in SEQ ID NO.1, and the mutation sites include: mutating Q at position 410 to N, mutating K at position 413 to T, mutating G at position 422 to F, mutating G at position 423 to R, mutating R at position 424 to S, mutating G at position 426 to P, mutating T at position 428 to A, and mutating S at position 429 to T, a total of 8 site mutation combinations (the amino acid residue numbers are numbered with reference to the full length of SEQ ID NO.1).

[0010] In a second aspect, the present invention provides a gene encoding the above-mentioned thermostable fatty acid photodecarboxylase mutant.

[0011] Based on the above technical solution, further, the nucleotide sequence of the gene is shown as SEQ ID NO.5.

[0012] In a third aspect, the present invention provides a recombinant plasmid into which is inserted a gene encoding the above-mentioned thermostable fatty acid photodecarboxylase mutant.

[0013] In a fourth aspect, the present invention provides a recombinant engineering strain that carries and is capable of expressing the above-mentioned recombinant plasmid.

[0014] Based on the above technical solution, further, the recombinant engineering strain is Escherichia coli.

[0015] In a fifth aspect, the present invention provides the use of the above-mentioned heat-resistant fatty acid photodecarboxylase mutant, a recombinant plasmid with a gene encoding the above-mentioned heat-resistant fatty acid photodecarboxylase mutant inserted therein, and a recombinant engineered bacterium carrying and capable of expressing the above-mentioned recombinant plasmid in catalyzing the decarboxylation of fatty acids to synthesize alkanes.

[0016] Based on the above technical solution, further, the fatty acid includes palmitic acid, lauric acid and myristic acid.

[0017] Based on the above technical solution, further, the reaction of catalyzing the decarboxylation of fatty acids to synthesize alkanes is carried out under conditions higher than the melting point of the fatty acids and without adding an organic solvent to assist dissolution.

[0018] Based on the above technical solution, further, the reaction temperature for catalyzing the decarboxylation of fatty acids to synthesize alkanes is 45-60°C, preferably 55-56°C, and is carried out in a conventional buffer solution and under blue light irradiation conditions.

[0019] Based on the above technical solution, further, the buffer solution includes Tris-HCl buffer solution and PBS buffer solution.

[0020] Based on the above technical solution, further, the buffer solution is 100mM Tris-HCl, pH 8.5.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] The present invention is directed to wild-type Chlorella variabilis-derived CvFAP, and a continuous 8-site combination mutant M8 (amino acid residue numbering is numbered with reference to the full length of SEQ ID NO.1) comprising Q410N, K413T, G422F, G423R, R424S, G426P, T428A, and S429T is constructed, and is used to catalyze palmitic acid or myristic acid to produce pentadecane or tridecane. The present invention confirms that the amino acid residues at positions 410, 413, 422, 423, 424, 426, 428, and 429 have a greater influence on the heat resistance of fatty acid photodecarboxylase, and the relative activity of the combination mutant M8 is 3 times higher than that of the wild-type CvFAP at 50°C. In particular, at 55°C, the combined mutant M8 can catalyze the efficient conversion of myristic acid into tridecane without the need for organic solvents such as dimethyl sulfoxide and methanol to dissolve the fatty acid substrate, while the wild-type CvFAP has almost no catalytic activity under the same conditions. The present invention provides a certain basis for improving the heat resistance of the enzyme, and its combined mutant M8 improves the application potential of the enzyme in the field of catalyzing fatty acids to produce biofuels in the absence of solvents. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The molecular dynamics analysis of CvFAP from Chlorella at different temperatures (300K and 330K) and the determination results of the unstable region 410-429.

[0024] Figure 2 This is a partial amino acid site distribution map of the 410-429 amino acid residue region with low structural stability obtained from the structural analysis of CvFAP derived from Chlorella.

[0025] Figure 3 This is a graph showing the affinity chromatography purification results of the CvFAP continuous site combination mutant M8.

[0026] Figure 4 is the melting temperature T of CvFAP (a) and combined mutant M8 (b) m Determination diagram of .

[0027] Figure 5 The t of CvFAP and combined mutant M8 1 / 2 Determination diagram.

[0028] Figure 6 This is the result diagram of the optimal reaction temperature of CvFAP and combined mutant M8.

[0029] Figure 7 This is a graph showing the catalytic activity of CvFAP and its combined mutant M8 on palmitic acid substrate at 50°C.

[0030] Figure 8 This is a graph showing the catalytic activity of CvFAP and its combined mutant M8 on myristic acid substrate at 55°C without a co-solvent.

[0031] Fig. 9 The standard curves for the quantitative analysis of pentadecane (a) and tridecane (b) by gas chromatography.

[0032] Fig.10 This is a gas chromatography analysis of each alkane and its retention time diagram. DETAILED DESCRIPTION

[0033] In order to better understand the above technical scheme, exemplary embodiments of the present invention will be described in more detail below. It should be understood that the present invention can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided in order to enable a clearer and more thorough understanding of the present invention, and to be able to fully convey the scope of the present invention to those skilled in the art.

[0034] Example 1 Structural stability analysis of fatty acid photodecarboxylase and screening of continuous site combination mutation sites

[0035] The structure of CvFAP from Chlorella (Protein Data Bank No. 5NCC) was used as the initial model, and the missing residue atoms were supplemented using spdbv. The AMBER14SB biomolecular force field was used to perform molecular dynamics simulations of the system at a temperature of 300K. The optimal substrate palmitic acid ligand was molecularly docked with the protein using Autodock after Gaussian optimization, and the topology file was generated using the sobtop program. The small molecule RESP charge was generated using Multiwfn. The TIP3P water model was used to minimize the system energy using the steepest descent method to eliminate poor initial contacts and stress. The cutoff distance was used to handle the real space interaction, and the PME method was used to handle the long-range electrostatic interaction. After energy minimization (maximum energy <1000 kJ / mol / nm), NVT equilibrium was performed at 300K and 330K with a time step of 2 fs and NPT equilibrium was performed at 1 bar pressure for 500 ps, ​​and finally a molecular dynamics simulation was performed for 100 ns. Finally, the structure was analyzed using RMSF and Pymol software. The results are shown in Figure 1 As shown in FIG. 1 , the amino acid site distribution of the amino acid residue region at positions 410-429, where the RMSF structure has low stability, is determined as follows: Figure 2 shown.

[0036] Example 2 Construction of continuous site combination mutants of fatty acid photodecarboxylase

[0037] After codon optimization for Escherichia coli, the entire sequence of the coding gene CvFAP (SEQ ID NO.4) from Chlorella fatty acid photodecarboxylase with the transduction peptide (amino acid residues 1-76) deleted was synthesized (corresponding to amino acid residues 77-645 in SEQ ID NO.1), and cloned into the BamⅠ / HindⅢ restriction site of the expression vector pET28a to obtain the recombinant plasmid pET28a-CvFAP. The CvFAP mutant provided by the present invention is obtained by mutation of the nucleotide sequence shown in SEQ ID NO.4, and the recombinant expression amino acid sequence of the wild-type CvFAP is SEQ ID NO.2.

[0038] Primers were designed to construct a mutant library, using the recombinant plasmid pET28a-CvFAP as a template and a pair of oligonucleotides with mutation sites as amplification primers. PrimeSTAR high-fidelity enzyme was used to amplify the fragment and the vector, and OK ClonDNA Ligation Kit II clone enzyme was used to connect the fragment and the vector to obtain a recombinant plasmid library with specific continuous mutation sites.

[0039] The target gene was amplified using the amplification primers shown in Table 1, where the underline indicates the mutation site, the primer name with F indicates the upstream primer, and the primer name with R indicates the downstream primer:

[0040] Table 1 Nucleotide sequences of amplification primers

[0041]

[0042]

[0043] PrimeSTAR Max high-fidelity enzyme and OK Clon DNA Ligation Kit II clone enzyme were used to amplify the CvFAP gene containing a specific mutation site. It is worth noting that the template plasmid, i.e., the wild-type plasmid, was mixed in the cloning system, so the template plasmid was removed by cleaving the PCR product with DpnⅠ. Then, 20 μL of the digested product was added to E. coli DH5α competent cells and spread on a LB solid plate containing 50 μg / mL kanamycin resistance. The plate colony library of the mutant was obtained by inverted culture at 37°C for 12 hours, and the relevant mutant sequence was confirmed to be correct by gene sequencing.

[0044] Example 3 Recombinant expression of fatty acid photodecarboxylase continuous site combination mutants

[0045] The plasmids constructed in Example 2 were transformed into competent E. coli BL21 (DE3) cells, and the strains carrying the above recombinant plasmids were selected on a plate containing kanamycin. The monoclonal strains carrying the above recombinant plasmids were picked from the plate and inoculated into 100 mL of TB liquid culture medium for overnight culture, and cultured at 37°C and 220 rpm for 2-3 h until the OD 600 The final concentration of IPTG was 0.3 mM, and the target protein was induced to express. The culture was continued for 20 h at 16 °C. The cells were collected by centrifugation at 4500 rpm for 15 min at 4 °C, and freeze-dried for subsequent experiments.

[0046] Example 4 Purification of fatty acid photodecarboxylase continuous site combination mutants

[0047] All target proteins were purified by Ni-NTA affinity chromatography. Recombinant E. coli expressing CvFAP or mutant M8 were collected by centrifugation and resuspended in buffer A (50mM PBS buffer, pH 8.5). After ultrasonic disruption, the cell lysate was centrifuged at 12,000g (4°C, 45min), and the supernatant was loaded onto a Ni-NTA affinity chromatography column pre-equilibrated in buffer A. The target proteins were then eluted by increasing the imidazole concentration from 10mM to 100mM and collected in different tubes. After SDS-PAGE analysis, the target proteins were collected and filtered into 50mM pH 8.5 PBS buffer to remove high concentrations of imidazole. The results are shown in Figure 2. Figure 3 The purified target protein was quickly frozen in liquid nitrogen and then stored at -80°C or used for subsequent testing.

[0048] Example 5 Fatty acid photodecarboxylase enzyme activity detection method and product quantitative analysis

[0049] The standard curve for the quantitative determination of the product alkanes was established by gas chromatography. A 1 mg / mL pentadecane standard solution was prepared using ethyl acetate as the solvent, and a pentadecane standard curve with a concentration range of 0.1 mg / mL–1 mg / mL was established. Pentadecane standard solutions of 0.1 mg / mL, 0.2 mg / mL, 0.4 mg / mL, 0.6 mg / mL, 0.8 mg / mL, and 1 mg / mL were prepared for gas chromatography analysis to obtain a standard curve for pentadecane. The relationship between the peak area and concentration of pentadecane is y=0.0019x+0.0017, R 2 =0.9999, where y represents the target product gas chromatography response peak area (mAU), and x represents the product pentadecane concentration (mM). Similarly, the standard curve of tridecane is obtained. The relationship between the peak area and concentration of tridecane is y=0.0022x+0.0048, R 2 = 0.9999, the standard curves of pentadecane and tridecane are as follows Fig. 9 shown.

[0050] The fatty acid photodecarboxylase reacts under 450nm blue light conditions at 50℃ and 55℃ respectively. The catalytic reaction of palmitic acid is carried out in 1.0mL Tris-HCl buffer (pH8.5, 100mM) containing 20% ​​DMSO as a co-solvent at 50℃, which is mainly used for mutant screening and activity evaluation. In addition, the catalytic reaction of myristic acid is carried out in 5.0mL Tris-HCl buffer (pH 8.5, 100mM) without DMSO as a co-solvent at 55℃. The reaction solution is extracted with two volumes of ethyl acetate and detected by gas chromatography. The specific detection conditions are: chromatographic column: HP-5 (250*4.6mm*5μm), nitrogen as carrier gas, split ratio 50:1, injection volume 1μL, injector temperature 250℃, detector temperature 300℃, nitrogen flow rate of 1mL / min, column box temperature changes are shown in Table 2, and the retention time of each alkane is as shown in Table 2. Fig.10 The enzyme activity was evaluated by the production of pentadecane and tridecane.

[0051] Table 2 Column box temperature gradient of gas chromatography

[0052]

[0053] Example 6 Thermal stability index of CvFAP and its mutant M8 Melting temperature T m Determination

[0054] Melting temperature T m The measurements were performed by a Bio-Logic MOS-500 spectrometer with a protein concentration of 0.05 mg / mL and dissolved in 50 mM phosphate buffer at pH 8.0. The CD spectra of CvFAP were collected at 0.1 nm intervals from 190 to 260 nm at 25 °C using a cuvette with a path length of 1 mm. The average of three scans was averaged and smoothed, processed using CDToolX-Windows 10 version software, and plotted as the average residue ellipticity (θ) in deg cm 2 For thermal denaturation measurements, ellipticity was measured at 222 nm from 20°C to 86°C at a rate of 90°C / h in 3°C increments. m ) was calculated by Boltzmann S-shape fitting using OriginLab OriginPro. The T of CvFAP was obtained by fitting. m The T of the combined mutant M8 was 49.24°C. m The temperature was 58.48℃, which was 9.24℃ higher than that of CvFAP. Figure 4 shown.

[0055] Example 7 Stability index of CvFAP and its mutant M8 1 / 2 Determination

[0056] CvFAP and its mutant M8 were mixed with the substrate and incubated at a controlled temperature of 50°C. Samples were taken out at regular intervals to measure the residual enzyme activity at 30°C. The time required for the initial activity of the enzyme to decrease by 50% was defined as the half-life (t 1 / 2 ). Using 10 mM palmitic acid as substrate and 1 mg of E. coli whole cell catalyst containing an equal amount of CvFAP or combined mutant M8, the reaction was carried out in 1.0 mL Tris-HCl buffer (pH 8.5, 100 mM) containing 20% ​​DMSO as a co-solvent under 450 nm blue light conditions, and the t of CvFAP was measured. 1 / 2 The t of combined mutant M8 was 55 min. 1 / 2 The time was 385 min, which was 7 times higher than that of CvFAP. Figure 5 shown.

[0057] Example 8 Determination of the optimal activity temperature of fatty acid photodecarboxylase mutants

[0058] The enzyme activities of CvFAP and its mutant M8 were measured at 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, and 60°C, respectively, and the temperature with the highest enzyme activity was defined as the optimal temperature of the enzyme. With 10mM palmitic acid substrate, in the reaction conditions of 1.0mL Tris-HCl buffer (pH 8.5, 100mM) containing 20% ​​DMSO as a co-solvent, and 1mg of Escherichia coli whole cell catalyst containing an equal amount of CvFAP or combined mutant M8, the analysis was performed after 15min of reaction under 450nm blue light conditions. The optimal temperature of CvFAP was measured to be 30°C, and the optimal temperature of combined mutant M8 was 45°C, which was 15°C higher than that of CvFAP. The results are as follows: Figure 6 shown.

[0059] Example 9 Determination of the heat-resistant activity of CvFAP and its mutant M8 at 50°C

[0060] CvFAP and its mutants were respectively subjected to enzyme activity and thermostable enzyme activity assay in a total volume of 1.0 mL Tris-HCl buffer (pH 8.5, 100 mM) containing 20% ​​DMSO as a co-solvent at 50°C. 0.2 mL of dimethyl sulfoxide containing palmitic acid (10 mM), 0.8 mL of Tris-HCl buffer (pH 8.5, 100 mM), and 1 mg of Escherichia coli whole cell catalyst containing an equal amount of CvFAP or combined mutant M8 were added to a transparent glass vial (total volume 1.5 mL). After reacting for 2 h under 450 nm blue light conditions, the substrate and product were extracted with twice the volume of ethyl acetate and detected by gas chromatography. The experimental results show that the conversion rate of CvFAP is 30%, and the conversion rate of combined mutant M8 is 90%. The results are as follows: Figure 7 shown.

[0061] Example 10 CvFAP and its mutant M8 catalyze the conversion of myristic acid into tridecane under cosolvent-free conditions

[0062] CvFAP and its mutants were tested for thermostable enzyme activity in a total volume of 1.0 mL Tris-HCl buffer (pH 8.5, 100 mM) without a cosolvent at 55°C. 10 mM myristic acid, 5 mL Tris-HCl buffer (pH 8.5, 100 mM), and 10 mg of Escherichia coli whole cell catalyst containing an equal amount of CvFAP or combined mutant M8 were added to a transparent glass bottle (total volume 10 mL). After reacting for 12 hours under 450 nm blue light, the substrate and product were extracted with twice the volume of ethyl acetate and detected by gas chromatography. The experiment showed that CvFAP was almost inactive, and the conversion rate of combined mutant M8 was 66%. The results are as follows Figure 8 shown.

[0063] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A thermostable fatty acid photodecarboxylase mutant, characterized in that: The amino acid sequence of the thermostable fatty acid photodecarboxylase mutant is shown in SEQ ID NO.

3.

2. A gene encoding the heat-resistant fatty acid photodecarboxylase mutant according to claim 1.

3. The gene according to claim 2, characterized in that The nucleotide sequence of the gene is shown in SEQ ID NO.

5.

4. A recombinant plasmid into which the gene according to claim 2 or 3 is inserted.

5. A recombinant engineering strain carrying and capable of expressing the recombinant plasmid according to claim 4.

6. The recombinant engineering strain according to claim 5, characterized in that The recombinant engineering strain is Escherichia coli.

7. Use of the thermostable fatty acid photodecarboxylase mutant according to claim 1, the recombinant plasmid according to claim 4, or the recombinant engineered bacteria according to claim 5 or 6 in catalyzing the decarboxylation of fatty acids to synthesize alkanes.

8. The use according to claim 7, characterized in that: The fatty acids include palmitic acid, myristic acid and lauric acid.

9. The use according to claim 7, characterized in that: The reaction of catalyzing the decarboxylation of fatty acids to synthesize alkanes is carried out under the condition that the temperature is higher than the melting point of the fatty acids and no organic solvent is added to assist dissolution.

10. The use according to claim 9, characterized in that: The reaction temperature for catalyzing the decarboxylation of fatty acids to synthesize alkanes is 45-60° C., preferably 55-56° C., and is carried out in a conventional buffer solution under blue light irradiation conditions.

Citation Information

Patent Citations

  • New fatty acid decarboxylase and its uses

    CN109477077A

  • Fatty acid photodecarboxylase mutant and application thereof to synthesis of L-phosphinothricin

    CN112063608A

  • Mutant of fatty acid light decarboxylase McFAP and application thereof

    CN114854726A

  • Mutant of fatty acid light decarboxylase CsoFAP and application thereof

    CN116790570A

  • New fatty acid decarboxylase and its uses

    US20190161771A1

Cited By

  • Method for producing sustainable aviation fuel main component by using photoenzyme decarboxylation reaction

    CN119709884A

  • Photo-decarboxylase mutant and application thereof in catalytic synthesis of aromatic compound

    CN122382042A